Woonsocket, Rhode Island headquartered CVS Health Corp.'s stock finished last Friday's session 0.96% higher at $82.20. A total volume of 7.09 million shares was traded. The Company's shares have advanced 3.50% in the past month and 4.17% since the start of this year. The stock is trading above its 50-day moving average by 4.15%. Additionally, shares of CVS Health, which together with its subsidiaries, provides integrated pharmacy health care services, have a Relative Strength Index (RSI) of 59.82.
On December 12th, 2016, research firm Jefferies downgraded the Company's stock rating from 'Buy' to 'Hold'.
On December 14th, 2016, CVS Health announced that the opioid overdose-reversal medication naloxone is now available without a prescription at all CVS Pharmacy locations in Nevada. CVS Health has established a standing order with physicians in Nevada that allows CVS Pharmacy to expand access to the medication across the state. See our free and comprehensive research report on CVS at: http://stock-callers.com/registration/?symbol=CVS
On Friday, shares in Minnetonka, Minnesota-based UnitedHealth Group Inc. ended the session 0.14% higher at $162.41. The stock recorded a trading volume of 3.08 million shares. The Company's shares have gained 3.24% in the last one month, 19.48% in the previous three months, and 1.48% on an YTD basis. The stock is trading 5.99% above its 50-day moving average and 16.15% above its 200-day moving average. Moreover, shares of UnitedHealth Group, which operates as a diversified health and well-being company in the US, have an RSI of 64.48.
On January 03rd, 2017, UnitedHealthcare and Qualcomm Incorporated, through its wholly owned subsidiary Qualcomm Life, Inc., announced enhancements and the expansion of UnitedHealthcare Motion™, a wellness program that provides employees with activity trackers at no additional charge and enables them to earn up to $1,500 per year by meeting certain goals for the number of daily steps. The two companies introduced UnitedHealthcare Motion in 2016 as a pilot in 12 states to select employers, using Qualcomm Life's 2net™ Platform* for medical-grade connectivity that features multiple safeguards to help keep data secure. Following the successful test, the program was expanded to 40 states.
On January 04th, 2017, research firm Piper Jaffray initiated an 'Overweight' rating on the Company's stock. UNH free research report PDF is just a click away at: http://stock-callers.com/registration/?symbol=UNH
St. Louis, Missouri headquartered Express Scripts Holding Co.'s shares declined 0.17%, closing the session at $70.75, with a total trading volume of 1.73 million shares. The stock has gained 0.57% over the previous three months and 2.85% on an YTD basis. Shares of the Company are trading 1.95% below their 50-day moving average. Additionally, shares of Express Scripts Holding, which operates as a pharmacy benefit management company in the US, Canada, and Europe, have an RSI of 50.54.
On December 14th, 2016, Express Scripts announced that it anticipates achieving adjusted earnings per diluted share for FY17 in the range of $6.82 to $7.02. The Company also announced that it is revising its methodology for reporting network claims for its 2017 financial guidance and for reporting periods beginning with the year ending December 31st, 2016. Solely as the direct result of the revised methodology, the Company is updating its previously issued FY16 total adjusted claims guidance from a range of 1,265 million to 1,280 million to a range of 1,400 million to 1,415 million. Sign up for your complimentary report on ESRX at: http://stock-callers.com/registration/?symbol=ESRX
Last Friday at the close, Dublin, Ireland headquartered Shire PLC's stock recorded a trading volume of 786,194 shares, and ended the session 1.04% lower at $180.11. The Company's shares have advanced 4.25% in the last month and 5.71% since the start of this year. The stock is trading above its 50-day moving average by 4.02%. Furthermore, shares of Shire, which together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products, have an RSI of 62.70.
On December 27th, 2016, Shire announced that the US FDA has approved ADYNOVATE, an extended circulating half-life recombinant Factor VIII treatment for hemophilia A, in pediatric patients under 12 years of age. The FDA also approved ADYNOVATE for use in surgical settings for both adult and pediatric patients. Register for free on Stock-Callers.com and download the latest research report on SHPG at: http://stock-callers.com/registration/?symbol=SHPG
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA